AbCellera Biologics Inc. (ABCL) |
|
7.135 -0.025 (-0.35%)
|
06-09 13:23 |
|
Open: |
7.19 |
Pre. Close: |
7.16 |
|
High:
|
7.23 |
Low:
|
7.02 |
|
Volume:
|
1,152,189 |
Market Cap:
|
2,060(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 12:43:06 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 8.83 One year: 10.31 |
| Support: |
Support1: 6.3 Support2: 5.53 |
| Resistance: |
Resistance1: 7.55 Resistance2: 8.83 |
| Pivot: |
6.87  |
| Moving Average: |
MA(5): 7.06 MA(20): 6.61
MA(100): 7.88 MA(250): 9.77 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 80.7 %D(3): 77.1 |
| RSI: |
RSI(14): 59.3 |
| 52-week: |
High: 14.97 Low: 5.53 |
| Average Vol(K): |
3-Month: 2,143 (K) 10-Days: 2,737 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABCL ] has closed below upper band by 29.5%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.36 - 7.39 |
7.39 - 7.42 |
|
Low:
|
6.9 - 6.95 |
6.95 - 6.98 |
|
Close:
|
7.09 - 7.16 |
7.16 - 7.21 |
|
Company Description |
|
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. |
Headline News |
Fri, 09 Jun 2023
American Century Companies Increases Stake in AbCellera ... - Best Stocks
Fri, 09 Jun 2023
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Bought by ... - MarketBeat
Thu, 08 Jun 2023
Guru Fundamental Report for ABCL - Benjamin Graham - Nasdaq
Wed, 07 Jun 2023
Should You Accumulate AbCellera Biologics Inc (ABCL) Stock Wednesday Morning? - InvestorsObserver
Mon, 29 May 2023
2023-05-29 | NDAQ:ABCL | Press Release | AbCellera Biologics Inc. - Stockhouse Publishing
Mon, 29 May 2023
AbCellera to Present at the Goldman Sachs 44th Annual Global ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
289 (M) |
| Shares Float |
210 (M) |
|
% Held by Insiders
|
28.6 (%) |
|
% Held by Institutions
|
46.4 (%) |
|
Shares Short
|
26,620 (K) |
|
Shares Short P.Month
|
23,590 (K) |
Stock Financials |
|
EPS
|
-0.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.19 |
|
Profit Margin (%)
|
-27.8 |
|
Operating Margin (%)
|
-40.5 |
|
Return on Assets (ttm)
|
-3 |
|
Return on Equity (ttm)
|
-4.2 |
|
Qtrly Rev. Growth
|
-96.1 |
|
Gross Profit (p.s.)
|
1.07 |
|
Sales Per Share
|
0.62 |
|
EBITDA (p.s.)
|
-0.16 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
133 (M) |
|
Levered Free Cash Flow
|
86 (M) |
Stock Valuations |
|
PE Ratio
|
-39.67 |
|
PEG Ratio
|
-1.2 |
|
Price to Book value
|
1.7 |
|
Price to Sales
|
11.38 |
|
Price to Cash Flow
|
15.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
